Cbio’s unique and proprietary REVITA technology platform enables development of clearly differentiated T-cell therapy products with transformative potential – products designed to revitalize T-cells, arm them against oxidative stress, securing a highly potent multitargeted T-cell product that effectively track down and kill cancer cells
Cancer cells only survive, if they somehow can avoid being recognized and killed by the immune system. When tumors grow out of control and metastasize, it is evident that cancer have had the upper hand in this battle. Many solid tumors have high levels of oxidative stress that further enables them to escape the immune system.
The core principle of T-cell therapy is basically to revert this imbalance and secure that enough tumor reactive T-cells are reinfused back into the patient to overcome the hostile tumor environment, thereby securing that the immune cells can track down and kill cancer cells all over the body.
Cbio’s unique REVITA technology is based on novel discoveries and in-depth understanding about the immune system and the tumor micro environment. T-cells are reinvigorated and armed against oxidative stress to enable them to maintaing killing functionality thereby giving the immune system the upper hand in the battle against cancer to the benefit of the patient.
Through decade-long research work at Prof. Rolf Kiessling's group at Karolinska Institute and structured discovery work at Cbio, we have have developed a first-in-class T-cell product that is now ready for the clinic.
T-cell therapy utilizes the patient’s own immune defense to combat cancer. In T-cell therapy, a piece of the tumor is resected from the patient and transported to the laboratory, where immune cells are extracted, stimulated with IL-2 and expanded to the billions. Following lymphodepleting therapy, the immune cells (primarily T-cells) are reinfused in the patient, where the TILs track down and eradicate the cancer.
Through structured discovery work, Cbio has developed a novel T-cell therapy product by adding a proprietary cocktail of stimulators in addition to IL-2 to the first step of the expansion phase thereby reinvigorating and growing the immune cells much faster and to higher numbers than the standard T-cell therapy approaches. In addition, based on in-licensed technologies from Prof. Rolf Kiessling group at Karolinska Institute, the T-cells are armed against oxidative stress opening up T-cell therapies to otherwise hard-to-treat cancer types.
These two major improvements leads to a unique first-in-class, improved T-cell product with transformative potential. It enables for minimally invasive therapy, as biopsies can be used instead of surgery, secures a T-cell product with a much broader T-cell repertoire that can unlock solid tumors with high levels of oxidative stress leaving less opportunities for the cancer to escape.
Cbio has perfected the T-cell manufacturing process with its proprietary Fast Lymphocyte Expansion (FLeX) protocol providing novoleucel with a number of differentiated benefits versus standard IL-2 only expanded T-cell therapies:
LESS STARTING MATERIAL
1-2 cm3
→
1-3 MM3
Allows for fine needle biopsy – 2-3 times more patients can be treated as no surgery is required
REDUCED PRODUCTION TIME
49 Days
→
22 Days
Time matters – the health of late-stage cancer patients can quickly deteriorate
HIGHER POTENCY
3X TUMOR REACTIVE
More tumor reactive T-cells in T-cell product – linked to improved clinical outcome
IMPROVED SUCCESS RATE
68%
→
98%
50% more patients can be offered novoleucel therapy – also in less immunogenic cancers
SCALABLE, LESS MANUAL STEPS
2,437
→
378
Manufacturability and scalability are critical parameters for a commercially viable T-cell product
CRYOPRESERVED FINAL PRODUCT
20°C
→
-180°C PRODUCT
With a cryopreserved final product formulation, novoleucel can be distributed globally
Based on proprietary, leading technology pushing the boundaries of where T-cell therapy can be applied
Intellectual property is of great importance and Cbio constantly seeks to protect and enhance proprietary technology, inventions, and improvements that are commercially important to the development of its business.
Through decade-long research, Prof. Rolf Kiessling's group at Karolinska Institute has developed a novel approach to arm T-cells against oxidative stress. Cbio has an exclusive license to this groundbreaking technology.
In addition, Cbio has further optimized the base TIL product with proprietary ex-vivo checkpoint inhibition and stimulation protecting novoleucel (patent pending) until 2040. In addition, Cbio has filed several patent applications covering further developments to the basic T-cell therapy technology.